The Minnesota Regional Peripheral Arterial Disease Screening Program: toward a definition of community standards of care

被引:70
作者
Hirsch, AT
Halverson, SL
Treat-Jacobson, D
Hotvedt, PS
Lunzer, MM
Krook, S
Rajala, S
Hunninghake, DB
机构
[1] Univ Minnesota, Sch Med, Vasc Med Program, Minnesota Vasc Dis Ctr, Minneapolis, MN 55455 USA
[2] Univ Minnesota, Sch Med, Dept Med, Div Cardiovasc,Heart Dis Prevent Clin, Minneapolis, MN 55455 USA
关键词
aspirin; atherosclerosis; cholesterol; claudication; peripheral arterial disease; quality of life;
D O I
10.1177/1358836X0100600204
中图分类号
R6 [外科学];
学科分类号
1002 [临床医学]; 100210 [外科学];
摘要
The Minnesota Regional Peripheral Arterial Disease Screening Program was designed to define the efficacy of community PAD detection efforts, to assess the disease-specific and health-related morbidity, to assess PAD awareness rates, and to determine the magnitude of atherosclerosis disease risk factors and the intensity of their management. The target population was recruited via mass media efforts directed at individuals over 50 years of age and those with leg pain with ambulation. Screening sessions included assessments of the ankle-brachial index, blood pressure, fasting lipid profile, and use of validated tools to detect symptomatic claudication (by the Modified WHO-Edinburgh Claudication Questionnaire), walking impairment (Walking Impairment Questionnaire - WIQ), quality of life (MOS SF-36), PAD awareness, and the intensity of PAD medical therapeutic interventions. PAD was defined as any ankle-brachial index less than or equal to0.85 or a history of lower extremity revascularization. The program evaluated 347 individuals and identified 92 subjects with PAD and 255 subjects without PAD, yielding a detection rate of 26.5%. Individuals with PAD were older, tended to have higher blood pressures, and had a significant walking impairment and an impaired health-related quality of life compared with the non-PAD subjects. Current rates of tobacco use were low. Lipid-lowering, estrogen replacement, anti-platelet, and anti hypertensive medications and exercise therapies were underutilized in the PAD cohort. Peripheral arterial disease awareness was low in these community-identified patients. This Program demonstrated that individuals with PAD can be efficiently identified within the community, but that current standards of medical care are low. These data can assist in the future development of PAD awareness, education, and treatment programs.
引用
收藏
页码:87 / 96
页数:10
相关论文
共 41 条
[1]
[Anonymous], 1994, BMJ, V308, P81, DOI [10.1136/bmj.308.6921.81, DOI 10.1136/BMJ.308.6921.81]
[2]
PREVALENCE OF COEXISTENCE OF CORONARY-ARTERY DISEASE, PERIPHERAL ARTERIAL-DISEASE, AND ATHEROTHROMBOTIC BRAIN INFARCTION IN MEN AND WOMEN GREATER-THAN-OR-EQUAL-TO-62 YEARS OF AGE [J].
ARONOW, WS ;
AHN, C .
AMERICAN JOURNAL OF CARDIOLOGY, 1994, 74 (01) :64-65
[3]
Black HR, 1997, ARCH INTERN MED, V157, P2413
[4]
THE NATURAL COURSE OF ARTERIOSCLEROSIS OF THE LOWER EXTREMITIES [J].
BOYD, AM .
PROCEEDINGS OF THE ROYAL SOCIETY OF MEDICINE-LONDON, 1962, 55 (07) :591-593
[5]
TRENDS IN THE PREVALENCE, AWARENESS, TREATMENT, AND CONTROL OF HYPERTENSION IN THE ADULT US POPULATION - DATA FROM THE HEALTH EXAMINATION SURVEYS, 1960 TO 1991 [J].
BURT, VL ;
CUTLER, JA ;
HIGGINS, M ;
HORAN, MJ ;
LABARTHE, D ;
WHELTON, P ;
BROWN, C ;
ROCCELLA, EJ .
HYPERTENSION, 1995, 26 (01) :60-69
[6]
THE PREVALENCE OF PERIPHERAL ARTERIAL-DISEASE IN A DEFINED POPULATION [J].
CRIQUI, MH ;
FRONEK, A ;
BARRETTCONNOR, E ;
KLAUBER, MR ;
GABRIEL, S ;
GOODMAN, D .
CIRCULATION, 1985, 71 (03) :510-515
[7]
MORTALITY OVER A PERIOD OF 10 YEARS IN PATIENTS WITH PERIPHERAL ARTERIAL-DISEASE [J].
CRIQUI, MH ;
LANGER, RD ;
FRONEK, A ;
FEIGELSON, HS ;
KLAUBER, MR ;
MCCANN, TJ ;
BROWNER, D .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (06) :381-386
[8]
TREATMENT OF INTERMITTENT CLAUDICATION - THE IMPACT ON QUALITY-OF-LIFE [J].
CURRIE, IC ;
WILSON, YG ;
BAIRD, RN ;
LAMONT, PM .
EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY, 1995, 10 (03) :356-361
[9]
CLINICAL-PHARMACOLOGY OF PENTOXIFYLLINE WITH SPECIAL REFERENCE TO ITS HEMORRHEOLOGIC EFFECT FOR THE TREATMENT OF INTERMITTENT CLAUDICATION [J].
DETTELBACH, HR ;
AVIADO, DM .
JOURNAL OF CLINICAL PHARMACOLOGY, 1985, 25 (01) :8-26
[10]
ERNST E, 1993, ARCH INTERN MED, V153, P2357